These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 21359109)

  • 1. Adoption and implementation of medications in addiction treatment programs.
    Knudsen HK; Abraham AJ; Roman PM
    J Addict Med; 2011 Mar; 5(1):21-7. PubMed ID: 21359109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perceptions of the state policy environment and adoption of medications in the treatment of substance use disorders.
    Knudsen HK; Abraham AJ
    Psychiatr Serv; 2012 Jan; 63(1):19-25. PubMed ID: 22227755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early adoption of injectable naltrexone for alcohol-use disorders: findings in the private-treatment sector.
    Abraham AJ; Roman PM
    J Stud Alcohol Drugs; 2010 May; 71(3):460-6. PubMed ID: 20409441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disparities in access to physicians and medications for the treatment of substance use disorders between publicly and privately funded treatment programs in the United States.
    Abraham AJ; Knudsen HK; Rieckmann T; Roman PM
    J Stud Alcohol Drugs; 2013 Mar; 74(2):258-65. PubMed ID: 23384373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A longitudinal examination of alcohol pharmacotherapy adoption in substance use disorder treatment programs: patterns of sustainability and discontinuation.
    Abraham AJ; Knudsen HK; Roman PM
    J Stud Alcohol Drugs; 2011 Jul; 72(4):669-77. PubMed ID: 21683049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Facilitating factors and barriers to the use of medications in publicly funded addiction treatment organizations.
    Knudsen HK; Roman PM; Oser CB
    J Addict Med; 2010 Jun; 4(2):99-107. PubMed ID: 20835350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Barriers to use of pharmacotherapy for addiction disorders and how to overcome them.
    Oliva EM; Maisel NC; Gordon AJ; Harris AH
    Curr Psychiatry Rep; 2011 Oct; 13(5):374-81. PubMed ID: 21773951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty.
    Mark TL; Kassed CA; Vandivort-Warren R; Levit KR; Kranzler HR
    Drug Alcohol Depend; 2009 Jan; 99(1-3):345-9. PubMed ID: 18819759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timing of buprenorphine adoption by privately funded substance abuse treatment programs: the role of institutional and resource-based interorganizational linkages.
    Savage SA; Abraham AJ; Knudsen HK; Rothrauff TC; Roman PM
    J Subst Abuse Treat; 2012 Jan; 42(1):16-24. PubMed ID: 21831565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoption of injectable naltrexone in U.S. substance use disorder treatment programs.
    Aletraris L; Bond Edmond M; Roman PM
    J Stud Alcohol Drugs; 2015 Jan; 76(1):143-51. PubMed ID: 25486403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicaid coverage of medications to treat alcohol and opioid dependence.
    Mark TL; Lubran R; McCance-Katz EF; Chalk M; Richardson J
    J Subst Abuse Treat; 2015 Aug; 55():1-5. PubMed ID: 25921475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability.
    Koch AL; Arfken CL; Schuster CR
    Drug Alcohol Depend; 2006 Jul; 83(3):274-8. PubMed ID: 16413146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Availability of addiction medications in private health plans.
    Horgan CM; Reif S; Hodgkin D; Garnick DW; Merrick EL
    J Subst Abuse Treat; 2008 Mar; 34(2):147-56. PubMed ID: 17499959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Financial factors and the implementation of medications for treating opioid use disorders.
    Knudsen HK; Roman PM
    J Addict Med; 2012 Dec; 6(4):280-6. PubMed ID: 22810057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissemination, adoption, and implementation of acamprosate for treating alcohol use disorders.
    Knudsen HK; Roman PM
    J Stud Alcohol Drugs; 2014 May; 75(3):467-75. PubMed ID: 24766759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapy for alcohol dependence: perceived treatment barriers and action strategies among Veterans Health Administration service providers.
    Harris AHS; Ellerbe L; Reeder RN; Bowe T; Gordon AJ; Hagedorn H; Oliva E; Lembke A; Kivlahan D; Trafton JA
    Psychol Serv; 2013 Nov; 10(4):410-419. PubMed ID: 23356858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment and treatment of co-occurring eating disorders in publicly funded addiction treatment programs.
    Gordon SM; Johnson JA; Greenfield SF; Cohen L; Killeen T; Roman PM
    Psychiatr Serv; 2008 Sep; 59(9):1056-9. PubMed ID: 18757602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoption and diffusion of evidence-based addiction medications in substance abuse treatment.
    Heinrich CJ; Cummings GR
    Health Serv Res; 2014 Feb; 49(1):127-52. PubMed ID: 23855719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International update: new findings on promising medications.
    Litten RZ
    Alcohol Clin Exp Res; 1996 Nov; 20(8 Suppl):216A-218A. PubMed ID: 8947268
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacotherapy of alcohol use disorders by the Veterans Health Administration: patterns of receipt and persistence.
    Harris AH; Oliva E; Bowe T; Humphreys KN; Kivlahan DR; Trafton JA
    Psychiatr Serv; 2012 Jul; 63(7):679-85. PubMed ID: 22549276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.